Bill
HD 2930
Massachusetts bill prohibits retaliation against hospitals and clinics participating in federal 340B drug discount program, protecting affordable medication access for vulnerable populations.
HD 2930 prohibits discrimination against healthcare entities and covered individuals who participate in the 340B drug discount program, a federal program that allows certain hospitals and clinics to purchase medications at significantly reduced prices. The bill would establish protections against retaliation or disadvantageous treatment by pharmaceutical manufacturers, pharmacy benefit managers (PBMs), insurers, or other entities based on 340B participation.
The 340B program helps safety-net hospitals, clinics serving vulnerable populations, and other covered entities stretch limited resources by reducing drug acquisition costs. Without anti-discrimination protections, manufacturers or intermediaries could threaten to exclude 340B participants from programs, increase prices selectively, or create barriers that effectively penalize participation. This directly affects affordability and access to medications for uninsured, underinsured, and low-income patients.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
